TGFB1 and hepatocellular carcinoma: In addition, Tregs may be a significant target for the immune suppression of HCC, and sorafenib, a key multikinase inhibitor for HCC treatment, reduces the frequency of Treg infiltration into the liver by suppressing the TGF-β signaling [79].